NWD1

Summary

NWD1 (NACHT and WD repeat domain containing 1, HGNC:27619) is a protein-coding gene on chromosome 19p13.11, encoding NACHT domain- and WD repeat-containing protein 1 (Q149M9). May play a role in the control of androgen receptor (AR) protein steady-state levels.

The protein encoded by this gene is thought to be a cytosolic protein and predicted to contain a NACHT domain and multiple WD40 repeats. Increased expression of this gene was observed in some prostate cancer cell lines. Knocking down expression of this gene results in decreased androgen receptor protein levels, indicating that this gene may be important in modulating androgen receptor activity. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 284434 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 287 total
• MANE Select transcript: NM_001007525

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27619
Approved symbol	NWD1
Name	NACHT and WD repeat domain containing 1
Location	19p13.11
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000188039
Ensembl biotype	protein_coding
OMIM	616250
Entrez	284434

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 protein_coding, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000438489, ENST00000518676, ENST00000524140, ENST00000549814, ENST00000552788, ENST00000646016, ENST00000673671, ENST00000673758, ENST00000673803, ENST00000674033, ENST00000674103

RefSeq mRNA: 3 — MANE Select: NM_001007525 NM_001007525, NM_001290355, NM_001347994

CCDS: CCDS32945

Canonical transcript exons

ENST00000524140 — 19 exons

Exon	Start	End
ENSE00002090255	16731192	16731278
ENSE00002126290	16724366	16724463
ENSE00002127748	16719847	16720293
ENSE00003483153	16744421	16744718
ENSE00003483233	16797732	16797886
ENSE00003492660	16807586	16808136
ENSE00003510619	16759225	16759428
ENSE00003533246	16779343	16779465
ENSE00003567646	16749139	16750411
ENSE00003575078	16799886	16800162
ENSE00003610640	16761979	16762138
ENSE00003610872	16765034	16765192
ENSE00003631302	16788982	16789190
ENSE00003645050	16736634	16736750
ENSE00003648710	16763828	16763945
ENSE00003672314	16773126	16773323
ENSE00003678312	16794463	16794553
ENSE00003691602	16791350	16791622
ENSE00003903931	16815028	16817953

Expression profiles

Bgee: expression breadth broad, 100 present calls, max score 91.74.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6581 / max 84.3671, expressed in 132 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
174440	0.2886	96
174441	0.1369	72
174438	0.1001	34
174439	0.0882	53
208719	0.0328	20
174442	0.0115	1

Top tissues by expression

118 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	91.74	gold quality
right uterine tube	UBERON:0001302	87.17	gold quality
corpus callosum	UBERON:0002336	78.64	gold quality
caudate nucleus	UBERON:0001873	76.78	gold quality
nucleus accumbens	UBERON:0001882	76.76	gold quality
temporal lobe	UBERON:0001871	74.02	gold quality
amygdala	UBERON:0001876	73.94	gold quality
putamen	UBERON:0001874	73.90	gold quality
anterior cingulate cortex	UBERON:0009835	72.48	gold quality
fallopian tube	UBERON:0003889	72.16	gold quality
right frontal lobe	UBERON:0002810	71.37	gold quality
Ammon’s horn	UBERON:0001954	71.31	gold quality
frontal cortex	UBERON:0001870	70.40	gold quality
cerebral cortex	UBERON:0000956	70.30	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	70.12	gold quality
prefrontal cortex	UBERON:0000451	69.75	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.56	gold quality
superior frontal gyrus	UBERON:0002661	69.39	gold quality
hypothalamus	UBERON:0001898	69.01	gold quality
prostate gland	UBERON:0002367	68.97	gold quality
primary visual cortex	UBERON:0002436	67.61	gold quality
substantia nigra	UBERON:0002038	67.46	gold quality
brain	UBERON:0000955	67.33	gold quality
endometrium	UBERON:0001295	64.84	gold quality
saliva-secreting gland	UBERON:0001044	62.27	gold quality
minor salivary gland	UBERON:0001830	61.78	gold quality
islet of Langerhans	UBERON:0000006	60.37	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	59.57	gold quality
body of stomach	UBERON:0001161	58.67	gold quality
stomach	UBERON:0000945	57.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.28
E-MTAB-4850	no	2.64

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
KLK3	Activation
SPDEF	Activation

Upstream regulators (CollecTRI, top): AR, SOX9, SRY

miRNA regulators (miRDB)

117 targeting NWD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-6733-5P	99.74	67.94	2759

Literature-anchored findings (GeneRIF, showing 2)

• Overexpression of NWD1 is associated with prostate cancer. (PMID:24681825)
• our study contributes to the understanding of the biological role of Nwd1 at the synapse and the characterization of the beneficial effects of Nwd1 in the treatment of seizures. (PMID:31474551)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nwd1	ENSMUSG00000048148
rattus_norvegicus	Sin3b	ENSRNOG00000048622

Paralogs (26): PAFAH1B1 (ENSG00000007168), SNRNP40 (ENSG00000060688), WDR62 (ENSG00000075702), WDR7 (ENSG00000091157), TBL2 (ENSG00000106638), PAK1IP1 (ENSG00000111845), WDR75 (ENSG00000115368), DCAF4 (ENSG00000119599), DAW1 (ENSG00000123977), TEP1 (ENSG00000129566), AHI1 (ENSG00000135541), WDR38 (ENSG00000136918), MAPKBP1 (ENSG00000137802), POC1B (ENSG00000139323), NEDD1 (ENSG00000139350), COP1 (ENSG00000143207), WDR17 (ENSG00000150627), WDR43 (ENSG00000163811), POC1A (ENSG00000164087), WDR88 (ENSG00000166359), WDR81 (ENSG00000167716), DCAF4L2 (ENSG00000176566), DCAF4L1 (ENSG00000182308), WDR27 (ENSG00000184465), WDR5 (ENSG00000196363), WDR5B (ENSG00000196981)

Protein

Protein identifiers

NACHT domain- and WD repeat-containing protein 1 — Q149M9 (reviewed: Q149M9)

All UniProt accessions (5): Q149M9, A0A669KAX7, A0A669KB99, E5RJJ1, F8W0U9

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the control of androgen receptor (AR) protein steady-state levels.

Subunit / interactions. May interact with HSP90AA1, HSP90AB1 and BAG2.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Expressed at highest levels in prostate, followed by testis, retina, trachea and optic nerve. Also detected in brain, epididymis, lung, vagina and pituitary. In the prostate, tends to be up-regulated during malignant progression compared to normal epithelium (at protein level).

Induction. May be up-regulated by SOX9 and SRY.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (3)

UniProt ID	Names	Canonical?
Q149M9-1	1	yes
Q149M9-2	2
Q149M9-3	3

RefSeq proteins (3): NP_001007526, NP_001277284, NP_001334923 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR007111	NACHT_NTPase	Domain
IPR011047	Quinoprotein_ADH-like_sf	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR024977	Apc4-like_WD40_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR043365	NWD1	Family
IPR057588	NWD1/2-like_WH	Domain

Pfam: PF00400, PF05729, PF12894, PF25469

UniProt features (35 total): repeat 14, sequence variant 7, sequence conflict 7, splice variant 4, chain 1, domain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q149M9-F1	80.57	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 341–348

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 58 (showing top): GOBP_NEGATIVE_REGULATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_REGULATION_OF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, chr19p13, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOBP_NEGATIVE_REGULATION_OF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, ARNT2_TARGET_GENES, DLX2_TARGET_GENES, E2F2_TARGET_GENES, HOXA7_TARGET_GENES, HOXB4_TARGET_GENES, NKX2_2_TARGET_GENES, SNAPC4_TARGET_GENES, SOX10_TARGET_GENES, UBN1_TARGET_GENES

GO Biological Process (2): positive regulation of gene expression (GO:0010628), obsolete negative regulation of NF-kappaB transcription factor activity (GO:0032088)

GO Molecular Function (3): ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (3): nucleolus (GO:0005730), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1528 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NWD1	CLVS2	Q5SYC1	494
NWD1	OR2G6	Q5TZ20	480
NWD1	NLRX1	Q86UT6	458
NWD1	ITPRID2	P28290	433
NWD1	OR51I2	Q9H344	425
NWD1	WDR74	Q6RFH5	420
NWD1	PJVK	Q0ZLH3	418
NWD1	INTS11	Q5TA45	408
NWD1	OR2H1	Q9GZK4	389
NWD1	GARIN2	Q8N9W8	386
NWD1	OR1Q1	Q15612	368
NWD1	F2RL3	Q96RI0	362
NWD1	CIITA	P33076	358
NWD1	INTS1	Q8N201	357
NWD1	NLRC5	Q86WI3	356

IntAct

5 interactions, top by confidence:

A	B	Type	Score
	NWD1	psi-mi:“MI:0915”(physical association)	0.400
NUDC	NWD1	psi-mi:“MI:0915”(physical association)	0.400
PLEKHA7	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
TSC22D3	VPS37C	psi-mi:“MI:0914”(association)	0.350

BioGRID (4): NWD1 (Affinity Capture-MS), NWD1 (Affinity Capture-MS), GAS7 (Cross-Linking-MS (XL-MS)), TPTE2 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A140LIF8, A0JN92, A1Z198, A6H603, B1ARD6, B1ARD8, D9I2F9, D9I2G1, D9I2G3, D9I2G4, D9I2H0, E1BPN0, G1SRW8, O02799, P0C7P3, P52630, Q08AF3, Q0GKD5, Q0P3U3, Q149M9, Q1LXZ7, Q1LZ50, Q2LKU9, Q2LKV5, Q2LKW6, Q32KW9, Q5I0J8, Q5NCI0, Q5RCZ8, Q5RFJ8, Q5SY16, Q5U311, Q60766, Q63035, Q68D06, Q6AYC2, Q6AYF9, Q6IEE8, Q6NXR0, Q7Z7L1

Diamond homologs: A0A223GEB2, A1L271, A6H603, G4MQX3, O14775, P23232, P25387, P62881, P62882, Q01369, Q04725, Q10051, Q149M9, Q5GIS3, Q5RDY7, Q61FW2, Q6NUD0, Q6PBY0, Q6PNB6, Q80ZD0, Q9BYB4, Q9WVB2, A1CJY4, A1D7I5, A2QEV8, A3LX18, A4RDD7, A5DGL8, A5DVY3, A6RUL1, A6ZMK5, A7EF03, A7RM20, A7TH19, A8QBF3, A8WVX8, B0BNA7, B0XFT7, B0XYC8, B3MVL6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

287 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	238
Likely benign	25
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

3502 predictions. Top by Δscore:

Variant	Effect	Δscore
19:16731286:G:GT	donor_gain	1.0000
19:16736706:G:GT	donor_gain	1.0000
19:16736748:GTT:G	donor_gain	1.0000
19:16736751:G:GG	donor_gain	1.0000
19:16750410:CGGTA:C	donor_loss	1.0000
19:16750411:GGT:G	donor_loss	1.0000
19:16750412:GTA:G	donor_loss	1.0000
19:16759427:AGG:A	donor_loss	1.0000
19:16759429:G:C	donor_loss	1.0000
19:16759430:T:A	donor_loss	1.0000
19:16761973:CTGTA:C	acceptor_loss	1.0000
19:16761974:TGTA:T	acceptor_loss	1.0000
19:16761975:GTA:G	acceptor_loss	1.0000
19:16761976:TA:T	acceptor_loss	1.0000
19:16761977:A:AG	acceptor_gain	1.0000
19:16761977:A:C	acceptor_loss	1.0000
19:16761978:G:A	acceptor_loss	1.0000
19:16761978:G:GG	acceptor_gain	1.0000
19:16761978:GACA:G	acceptor_gain	1.0000
19:16762138:GGTGA:G	donor_loss	1.0000
19:16763936:G:GT	donor_gain	1.0000
19:16765032:A:AG	acceptor_gain	1.0000
19:16765032:A:G	acceptor_loss	1.0000
19:16765033:G:GG	acceptor_gain	1.0000
19:16765033:GGC:G	acceptor_gain	1.0000
19:16765033:GGCA:G	acceptor_gain	1.0000
19:16773320:AAAGG:A	donor_loss	1.0000
19:16773322:AGGT:A	donor_loss	1.0000
19:16773323:GGT:G	donor_loss	1.0000
19:16773324:G:GA	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000070671 (19:16760695 A>G), RS1000100392 (19:16780219 A>C), RS1000156594 (19:16738210 G>T), RS1000174586 (19:16809736 T>C), RS1000175006 (19:16780446 G>A), RS1000207150 (19:16772514 C>T), RS1000217945 (19:16812397 G>A), RS1000225974 (19:16736052 C>A), RS1000242811 (19:16735362 C>T), RS1000248358 (19:16794765 T>A,C), RS1000266497 (19:16751659 G>A,C), RS1000306151 (19:16812064 A>T), RS1000335686 (19:16767051 G>A,C), RS1000368376 (19:16767329 G>A,C), RS1000376371 (19:16778908 C>G)

Disease associations

OMIM: gene MIM:616250 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003830_50	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005921	FEV change measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — WD repeat-containing proteins

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression, affects methylation	2
Smoke	decreases expression, increases abundance, increases expression	2
Particulate Matter	affects methylation, increases abundance, affects expression	2
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation, affects methylation	1
Methapyrilene	increases methylation	1
Nitrogen Dioxide	affects methylation, increases abundance	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer